EP Patent

EP3753549A1 — Liposomal doxorubicin formulation, method for producing a liposomal doxorubicin formulation and use of a liposomal doxorubicin formulation as a medicament

Assigned to Innomedica Holding AG · Expires 2020-12-23 · 5y expired

What this patent protects

The present invention relates to a liposomal doxorubicin formulation, a method for producing a liposomal doxorubicin formulation and a liposomal doxorubicin formulation for use as a medicament, in particular for use in the treatment of cancer, uterine leiomyosarcoma and adnexal s…

USPTO Abstract

The present invention relates to a liposomal doxorubicin formulation, a method for producing a liposomal doxorubicin formulation and a liposomal doxorubicin formulation for use as a medicament, in particular for use in the treatment of cancer, uterine leiomyosarcoma and adnexal skin cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP3753549A1
Jurisdiction
EP
Classification
—
Expires
2020-12-23
Drug substance claim
No
Drug product claim
No
Assignee
Innomedica Holding AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.